TGTX logo

TG Therapeutics, Inc.


TGTX: TG Therapeutics Inc is a fully-integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.


Show TGTX Financials

Consumer Interest
SEC Filings

Recent trades of TGTX by members of U.S. Congress

Recently reported changes by institutional investors

Quarterly net insider trading by TGTX's directors and management

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

Quiver Logo

No new patents for this ticker

U.S. Patents Dashboard

Number of mentions of TGTX in WallStreetBets Daily Discussion


Recent insights relating to TGTX

CNBC Recommendations

Recent picks made for TGTX stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in TGTX

Corporate Flights

Flights by private jets registered to TGTX